Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Wagner, A. J., Riedel, R. F., Van Tine, B., Chugh, R., Ganjoo, K. N., Cranmer, L. D., Pollack, S., Sankhala, K., Gordon, E., Ravi, V., Hornick, J. L., Kwiatkowski, D. J., Grigorian, B., Desai, N., Dickson, M. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.TPS11589

View details for Web of Science ID 000442916008050